Filing Details
- Accession Number:
- 0001410598-11-000004
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-07-05 17:32:34
- Reporting Period:
- 2011-06-28
- Filing Date:
- 2011-07-05
- Accepted Time:
- 2011-07-05 17:32:34
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1094847 | Oncovista Innovative Therapies Inc | OVIT | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1410598 | L Alexander Weis | 14785 Omicron Drive Suite 104 San Antonio TX 78245 | President, Ceo, Cfo, Secretary | Yes | Yes | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Shares Of Common Stock | Acquisiton | 2011-06-28 | 2,500 | $0.56 | 5,321,500 | No | 4 | P | Direct | |
Shares Of Common Stock | Acquisiton | 2011-06-28 | 1,000 | $0.57 | 5,322,500 | No | 4 | P | Direct | |
Shares Of Common Stock | Acquisiton | 2011-06-28 | 11,500 | $0.58 | 5,334,000 | No | 4 | P | Direct | |
Shares Of Common Stock | Acquisiton | 2011-06-29 | 200 | $0.55 | 5,334,200 | No | 4 | P | Direct | |
Shares Of Common Stock | Acquisiton | 2011-06-30 | 1,000 | $0.54 | 5,335,200 | No | 4 | P | Direct | |
Shares Of Common Stock | Acquisiton | 2011-06-30 | 5,000 | $0.55 | 5,340,200 | No | 4 | P | Direct | |
Shares Of Common Stock | Acquisiton | 2011-06-30 | 14,000 | $0.65 | 5,354,200 | No | 4 | P | Direct | |
Shares Of Common Stock | Acquisiton | 2011-06-30 | 2,000 | $0.61 | 5,356,200 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct | |
No | 4 | P | Direct |